Core Viewpoint - CITIC Securities believes that despite potential short-term market volatility, any downturn presents a better opportunity for positioning, with a focus on preparing for the year-end market rally [1] Market Strategy - The strategy emphasizes opportunistic positioning ahead of key events, specifically the Federal Reserve's interest rate meeting and the Central Economic Work Conference after December 10 [1] - Investors are advised to increase positions at lower levels before these meetings, paying attention to the support at the half-year line and market volume conditions [1] Reasons for Year-End Rally - The anticipated year-end rally is attributed to several factors: early spring market enthusiasm, expected liquidity improvement signals from potential Federal Reserve rate cuts, policy expectations for the start of the 14th Five-Year Plan, and similarities to the year-end rally in December 2020 [1] Key Investment Areas - CITIC Securities identifies several sectors likely to lead the year-end rally, including: - AI (CPO, AI applications, liquid cooling) - New Energy (energy storage, solid-state batteries, nuclear power) - Innovative pharmaceuticals - Machinery (humanoid robots, automation equipment) - Non-ferrous metals - Chemicals - Additionally, opportunities in Hong Kong's internet and commercial aerospace sectors are highlighted [1] Industry Focus - Key industries to monitor include: - Non-ferrous metals (copper, silver) - AI (communications, computing) - New Energy - Innovative pharmaceuticals - Machinery - Hong Kong internet - Chemicals [1] Thematic Focus - The primary thematic focus is on commercial aerospace [1]

盘前要闻 1、涉及中际旭创、胜宏科技等，沪深300等A股多条重要指数样本股调整 类型：公司 情绪影响：正面 情绪影响：正面 截至11月30日，《疯狂动物城2》累计票房已突破19.2亿元，超越前作在中国内地创下的15.4亿元票房纪 录，并以惊人速度刷新纪录。中泰证券认为，今年是动画电影大年，电影行业迎来供给与结构改善。相 关电影上市公司有望获益，如优质内容供给及引进方及电影院线等上市企业。 3、产需两端均改善，11月制造业PMI小幅回升！机构预期稳增长措施将出台 类型：宏观 情绪影响：正面 国家统计局数据显示，11月份，制造业采购经理指数(PMI)为49.2%，比上月上升0.2个百分点，景气水 平有所改善。东方金诚分析师王青认为，不排除年底前出台新的稳增长措施的可能。其中，年底前财政 促消费力度有可能加大，央行还可能实施新一轮降息降准。 4、央行等部门首次公开定调稳定币，继续坚持对虚拟货币的禁止性政策 类型：行业 沪深300、中证500、上证50等多个重要指数将调整指数样本。华电新能、东山精密、指南针、胜宏科技 等调入沪深300指数；华工科技、光启技术、中际旭创、胜宏科技等调入中证A50指数；上证50指数更 换 ...

□本报记者 王宇露 上周市场反弹，中证新华社民族品牌工程指数上涨2.08%，报1978.41点。兆易创新（603986）、中际旭 创（300308）、北方华创（002371）等成分股上周表现强势；下半年以来，中际旭创、阳光电源 （300274）、兆易创新等成分股涨幅居前。 展望后市，机构认为，短期不确定性因素减少，下行风险释放较为充分，后续股市可能表现为震荡修 复。从中长期视角看，此轮大行情的基础并未发生改变。 下半年以来，中际旭创上涨253.10%，排在涨幅榜首位；阳光电源上涨171.64%，居次席；兆易创新上 涨60.89%；亿纬锂能（300014）、盐湖股份（000792）、我武生物涨逾50%；宁德时代（300750）、中 微公司、澜起科技、达仁堂（600329）涨逾40%；科沃斯（603486）、以岭药业、安集科技、国瓷材 料、药明康德（603259）、北方华创、信立泰涨逾30%；中国中免（601888）、中兴通讯、中芯国际、 长白山（603099）、泸州老窖（000568）、芒果超媒（300413）涨逾20%；恒瑞医药、安琪酵母、海尔 智家（600690）、锦江酒店（600754）、双汇发展（000 ...

上周品牌工程指数多只成分股表现强势。具体来说，兆易创新上涨11.23%，排在涨幅榜首位；中际旭 创上涨10.88%，居次席；北方华创、中兴通讯涨逾10%；阳光电源、安集科技涨逾8%；丸美生物和安 琪酵母分别上涨7.89%和5.40%；我武生物、迈瑞医疗、国瓷材料、恒瑞医药、澜起科技涨逾4%；广联 达、紫光股份、恒生电子、豪威集团、以岭药业、长电科技涨逾3%；老板电器、信立泰、泰格医药、 华谊集团、盾安环境等多只成分股涨逾2%。 □本报记者 王宇露 上周市场反弹，中证新华社民族品牌工程指数上涨2.08%，报1978.41点。兆易创新、中际旭创、北方华 创等成分股上周表现强势；下半年以来，中际旭创、阳光电源、兆易创新等成分股涨幅居前。 展望后市，机构认为，短期不确定性因素减少，下行风险释放较为充分，后续股市可能表现为震荡修 复。从中长期视角看，此轮大行情的基础并未发生改变。 多只成分股表现强势 上周市场反弹，上证指数上涨1.40%，深证成指上涨3.56%，创业板指上涨4.54%，沪深300指数上涨 1.64%，品牌工程指数上涨2.08%，报1978.41点。 从中长期视角看，星石投资认为，此轮大行情的基础并未发生 ...

Core Viewpoint - The innovative drug sector has experienced fluctuations in the past two months, but significant capital inflows continue through innovative drug-themed ETFs, indicating ongoing investment value in the sector despite recent adjustments [1][2]. Group 1: Market Performance - The innovative drug sector has shown impressive performance this year, with several innovative drug-themed funds doubling in value. However, as of November 27, the average decline in these funds is approximately 10% [2]. - In the fourth quarter, innovative drug-themed ETFs have seen a net subscription amounting to 193.26 billion yuan, with notable contributions from various ETFs, including 36.17 billion yuan from Huatai-PineBridge and 33.2 billion yuan from GF [2]. - The total scale of several innovative drug-themed ETFs has significantly increased this year, with GF's ETF growing from 7.875 billion yuan to 25.505 billion yuan, and Huatai-PineBridge's ETF from 650 million yuan to 24.209 billion yuan [2]. Group 2: Fund Company Movements - Recent movements from fund companies indicate an increased focus on innovative drug-themed products, with multiple ETFs being reported since November 21, including those from GF and Yongan [3]. Group 3: Investment Focus - The innovative drug sector's adjustment is attributed to a mismatch between high-frequency market expectations and the actual pace of industry developments, leading to a need for selective stock picking in the future [4]. - Industry experts suggest that the phase of broad increases in the innovative drug sector may be over, and the next two years will likely see significant differentiation among companies, emphasizing those that have reached breakeven and are expected to sustain high growth in revenue and profits [4]. - The rise of the innovative drug industry in China reflects the country's advantages in talent, cost, and efficiency, with substantial growth potential for quality companies in the international market over the next three years [4][5].

Core Insights - Private equity firms have conducted over 44,000 research activities on A-share listed companies this year, with a focus on hard technology sectors such as electronics, biomedicine, and machinery [1][3] - Future investment focus will be on artificial intelligence, innovative pharmaceuticals, new consumption trends, and structural opportunities arising from "anti-involution" policies [2][6] Group 1: Research Activity Overview - A total of 2,579 private equity firms have participated in A-share research activities, covering 2,184 stocks across 30 primary industries, with a total of 44,702 research instances [3] - The top three industries by research frequency are electronics (8,732 times), biomedicine (6,341 times), and machinery (5,437 times) [3] - Notable stocks in the electronics sector include Luxshare Precision, which was researched 335 times, followed by Langchao Technology and Crystal Optoelectronics [3][4] Group 2: Key Private Equity Firms - Zhengyuan Investment has been the most active, conducting 1,002 research activities this year [3] - Other significant firms include Panjing Investment, Gao Yi Asset, and Danshui Spring, with research activities of 429, 389, and 319 times respectively [3][4] - Panjing Investment has shown particular interest in stocks with three or more research instances, including Luxshare Precision and Jiangbolong [4] Group 3: Sector Insights - The electronics industry is leading due to accelerated domestic substitution in semiconductors and the initiation of a consumer electronics innovation cycle [5] - The biomedicine sector is favored for its diverse stock options and the acceleration of innovative drug approvals, alongside a recovery in medical consumption [5] - The power equipment sector benefits from the continuous growth in new energy installations, attracting significant research interest from private equity firms [5] Group 4: Market Trends and Future Outlook - The market is transitioning from valuation-driven to earnings-driven, with a focus on high-growth sectors such as AI, innovative pharmaceuticals, and machinery [6][7] - Investment strategies are being adjusted to optimize portfolios in high-prosperity industries while preparing for potential style shifts [7] - There is an increasing emphasis on individual stock performance, with a focus on sectors that show structural growth potential without relying on overall economic recovery [7]

Core Insights - The article highlights that private equity firms have conducted over 44,000 research activities on A-share listed companies in China this year, with a strong focus on hard technology sectors such as electronics, biomedicine, and machinery [2][4]. Group 1: Research Activities - A total of 2,579 private equity firms participated in A-share research activities, covering 2,184 stocks across 30 primary industries, with 44,702 total research instances [4]. - The top three industries by research frequency are electronics (8,732 times), biomedicine (6,341 times), and machinery (5,437 times) [4]. - Notable stocks in the electronics sector include Luxshare Precision, which was researched 335 times, and other prominent companies in the biomedicine sector such as United Imaging Healthcare and Mindray Medical [4][5]. Group 2: Investment Focus - Private equity firms are increasingly interested in sectors like artificial intelligence, innovative pharmaceuticals, and new consumption trends, as well as structural opportunities arising from "anti-involution" policies [2][9]. - The electronics industry is leading due to accelerated domestic semiconductor replacement and the initiation of a consumer electronics innovation cycle [7]. - The biomedicine sector is favored for its diverse stock options and the rapid approval of innovative drugs, while the power equipment sector benefits from the continuous growth of new energy installations [7]. Group 3: Market Outlook - The article suggests that the market is transitioning from valuation-driven to performance-driven, with a focus on high-growth sectors such as AI, innovative pharmaceuticals, and machinery [9]. - There is an expectation that individual stock performance will become more significant than sector performance in the future, with a focus on areas that show structural growth potential [9]. - Investment strategies are being adjusted to account for market corrections and style rebalancing, with an emphasis on sectors that can maintain profitability without relying on overall economic recovery [9].

Core Insights - Private equity firms have conducted over 44,000 research activities on A-share listed companies in 2023, with a focus on hard technology sectors such as electronics, biomedicine, and machinery [1][2] - The most researched industries include electronics, biomedicine, and machinery, with significant interest in artificial intelligence, innovative pharmaceuticals, and new consumption trends [1][4] Group 1: Research Activities - A total of 2,579 private equity firms participated in A-share research, covering 2,184 stocks across 30 primary industries, resulting in 44,702 research instances [2] - The electronics sector was the most researched, with 8,732 instances, followed by biomedicine with 6,341 and machinery with 5,437 [2][4] - Notable companies in the electronics sector include Luxshare Precision, which was researched 335 times, and other leading firms in biomedicine such as United Imaging Healthcare and Mindray Medical [2][3] Group 2: Private Equity Firm Activities - The most active private equity firm, Zhengyuan Investment, conducted 1,002 research activities, while other major firms like Panjing Investment and Gao Yi Asset also showed high engagement [2][3] - Panjing Investment focused on nearly 30 stocks with multiple research instances, including Luxshare Precision and Jiangbolong [3] - Gao Yi Asset showed a preference for biomedicine, electronics, and machinery, conducting six research activities on Zhongkong Technology [3] Group 3: Market Trends and Insights - The electronics industry is thriving due to accelerated domestic semiconductor replacement and the initiation of a consumer electronics innovation cycle [4] - The biomedicine sector is favored for its diverse stock options and the rapid approval of innovative drugs, alongside a recovery in medical consumption [4] - The power equipment sector benefits from the continuous growth of new energy installations, attracting significant research interest from private equity firms [4] Group 4: Future Outlook - The market is expected to shift from valuation-driven to performance-driven, with a focus on high-growth sectors such as artificial intelligence, innovative pharmaceuticals, and machinery [5][6] - Investment strategies will emphasize structural growth potential in emerging sectors and cyclical opportunities arising from "anti-involution" policies [6]

Core Viewpoint - Major brokerages are focusing on the upcoming 2026 market outlook while still identifying opportunities in December 2025, with terms like "cross-year market" and "spring excitement" frequently mentioned [1] Group 1: Broker Strategies - CITIC Securities emphasizes the need for significant changes in domestic demand to unlock market potential, suggesting a focus on resource and traditional manufacturing sectors [3] - CITIC Jiantou advocates for strategic positioning ahead of the cross-year market, highlighting the importance of the Federal Reserve's meeting and the Central Economic Work Conference [4] - Huazhong Securities notes that the upcoming Central Economic Work Conference is expected to align with market expectations, while also suggesting that the AI industry remains a core focus [6] - China Galaxy observes frequent style shifts in the A-share market, indicating a cautious investor sentiment as the year-end approaches [13] - Shenwan Hongyuan discusses the potential for a spring market rally, suggesting that the current market adjustments may lead to a recovery phase [16] Group 2: Economic Indicators - Economic data shows a continued slowdown, with November retail sales expected to grow by approximately 2.6% year-on-year, while fixed asset investment is projected to decline by 1.8% [8] - The market is experiencing high volatility, with significant sector rotation observed, particularly between high-growth and low-valuation stocks [9] - The overall economic environment remains challenging, with PMI data indicating a contraction in manufacturing and services sectors [37] Group 3: Industry Focus - Key sectors identified for potential growth include AI applications, renewable energy, innovative pharmaceuticals, and mechanical equipment [5][38] - The AI industry is highlighted as a primary investment focus, particularly in areas such as computing power and software applications [10] - The focus on sectors benefiting from supply-demand improvements, such as storage and energy chains, is emphasized as a strategic investment direction [10] Group 4: Market Outlook - The market is expected to enter a phase of cross-year positioning, with significant attention on policy developments from the Central Economic Work Conference [34] - The potential for a spring market rally is anticipated, driven by macroeconomic data and liquidity conditions [40] - The upcoming year is projected to see a shift towards growth sectors, particularly in technology and renewable energy, as the market adjusts to new economic realities [41]

国家航天局已于近期设立商业航天司，相关业务正在逐步开展，标志着我国商业航天产业迎来专职监管 机构，未来将持续推动我国商业航天高质量发展，产业链有望全线受益。 机构后市投资观点 在经历震荡调整后，本周A股三大股指呈现小幅反弹趋势，但整个11月三大股指均收跌。展望即将到来 的12月行情，机构认为，或以结构性行情为主，市场即将迎来重要政策时间窗口，美联储议息会议表态 对全球市场流动性的潜在影响也值得关注。 在具体配置上，红利等防御性板块配置关注度升温，AI应用、资源品、医药生物、新消费方向投资机 会值得重视。面对波动行情，建议从中长期视角布局，利用市场的短期波动，以更合理的价格买入长期 看好的公司。 影响后市投资大事件 11月PMI上升0.2个百分点 国家统计局11月30日发布数据显示，11月份，制造业采购经理指数（PMI）为49.2%，比上月上升0.2个 百分点。11月份，生产指数和新订单指数分别为50.0%和49.2%，分别比上月上升0.3个百分点和0.4个百 分点。11月份，高技术制造业PMI为50.1%，连续10个月位于临界点以上。 央行召开打击虚拟货币交易炒作工作协调机制会议 11月28日，中国人民银行召 ...